RxDoctor Payments Data

Susan Rivera

Adult Health · Dunedin, FLNPI 1114918786

Payments from drug & device makers

$6,678in general payments, 2019–2025

Across 286 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$880
  • Amgen$573
  • Lilly USA, LLC$554
  • AstraZeneca$432
  • Novartis$277
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,678 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$162,758
Medicare patients
264
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$116,274
XareltoRivaroxaban39$41,192
RybelsusSemaglutide19$30,349
EliquisApixaban30$28,057
Tresiba Flextouch U-100Insulin Degludec46$26,569
JardianceEmpagliflozin21$15,168
JanuviaSitagliptin Phosphate18$13,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,231
MounjaroTirzepatide11$11,020
EntrestoSacubitril/Valsartan11$9,687
Breo ElliptaFluticasone/Vilanterol11$5,149
PremarinEstrogens, Conjugated15$5,084
SymbicortBudesonide/Formoterol Fumarate19$5,001
BrilintaTicagrelor11$4,721
Albuterol Sulfate HfaAlbuterol Sulfate133$4,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,906$146,62497 claims
PfizerEliquis, Premarin$233$33,14145 claims
GSKTrelegy Ellipta, Breo Ellipta$21$18,37930 claims
MerckJanuvia$36$13,60118 claims
Lilly USA, LLCMounjaro$554$11,02011 claims
AstraZenecaSymbicort, Brilinta$432$9,72230 claims
NovartisEntresto$277$9,68711 claims
AbbVieSynthroid$880$1,42831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.

Other adult health in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →